PDCD1 and neoplasm: As these activated T cells are potentially tumor-specific infiltrating T cells (either endogenous or adoptively transferred T cells modified to express tumor-specific TCR or CARs), preventing the binding between PD-1 and PD-L1 might rescue antitumor T cell cytotoxicity and result in increased efficacy of cell-based immunotherapies.